- Home
- ACIU vs GLO Comparison
ACIU vs GLO Comparison
Compare ACIU & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | GLO |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 242.9M |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ACIU | GLO |
|---|---|---|
| Price | $2.70 | $5.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 205.6K | 119.5K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $635.38 | N/A |
| Revenue Next Year | $232.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $4.45 |
| 52 Week High | $4.00 | $6.09 |
Technical Indicators
Market Signals| Indicator | ACIU | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 43.55 |
| Support Level | $2.57 | $5.37 |
| Resistance Level | $2.99 | $5.58 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.05 | 44.05 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.